Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?

doi:10.4252/wjsc.v7.i2.408

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5159)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

353

WORD

207

HTML

2823

Figures (1-1)

100

Sum=3483

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

890

Download

786

Sum=1676

Mar 26, 2015 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Mar 26, 2015; 7(2): 408-417
Published online Mar 26, 2015. doi: 10.4252/wjsc.v7.i2.408

Open in New Tab Full Size Figure Download Figure

Figure 1 Paradoxical effect of donor mesenchymal stem cells in cancer and infection development. MSCs: Mesenchymal stem cells; TLR2: Toll-like receptor.

Citation: Arango-Rodriguez ML, Ezquer F, Ezquer M, Conget P. Could cancer and infection be adverse effects of mesenchymal stromal cell therapy? World J Stem Cells 2015; 7(2): 408-417
URL: https://www.wjgnet.com/1948-0210/full/v7/i2/408.htm
DOI: https://dx.doi.org/10.4252/wjsc.v7.i2.408